Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BI-847325

Known as: BI 847325, MEK/Aurora Kinase Inhibitor BI 847325 
An orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AbstractBackgroundAnaplastic thyroid carcinoma (ATC) is the most lethal malignancy in thyroid carcinomas. Long non-coding RNAs… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Although the MAPK pathway is frequently deregulated in cancer, inhibitors targeting RAF or MEK have so far shown clinical… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Resistance to BRAF inhibitors is a major clinical problem. Here, we evaluate BI-847325, an ATP-competitive inhibitor of MEK and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
AbstractPurpose This study determined the safety, maximum tolerated dose (MTD), pharmacokinetics, and preliminary efficacy of BI… Expand
  • table 1
  • table 2
  • table 3
  • table 5
  • figure 1
Is this relevant?
2015
2015
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA BACKGROUND: BRAF/MEK inhibitors have shown… Expand
Is this relevant?